Breast Conservation Surgery Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
CONCLUSIONS: Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted.CLINICAL TRIAL REGISTRATION: ChiCTR2100046678.PMID:38459836 | DOI:10.1093/oncolo/oyae033 (Source: The Oncologist)
Source: The Oncologist - March 9, 2024 Category: Cancer & Oncology Authors: Hongmeng Zhao Dan Li Qian Li Bin Zhang Chunhua Xiao Ying Zhao Jie Ge Yue Yu Yumian Jia Xiaojing Guo Xuchen Cao Xin Wang Source Type: research

Cancers, Vol. 16, Pages 1105: Combined Ultrahypofractionated Whole-Breast Irradiation and IORT-Boost: A Safety and Feasibility Analysis
Conclusions: Our results confirm for the first time that the combination of ultrafractionation WBI and photon-IORT after BCS is a feasible and safe option in patients with early BC. (Source: Cancers)
Source: Cancers - March 9, 2024 Category: Cancer & Oncology Authors: Javier Burgos-Burgos V íctor Vega David Macias-Verde Virginia G ómez Elena Vicente Carmen Murias Carlos Santana Pedro C. Lara Tags: Article Source Type: research

Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study
CONCLUSIONS: This dual HER2-blockade with sequential polychemotherapy showed promising activity with rapid tumor regression in HER2-positive BC. Importantly, this regimen showed an acceptable safety profile, especially a low risk of cardiac events, suggesting it as an attractive treatment approach with a favorable risk-benefit balance.PMID:38455369 | PMC:PMC10915636 | DOI:10.21147/j.issn.1000-9604.2024.01.06 (Source: Cancer Control)
Source: Cancer Control - March 8, 2024 Category: Cancer & Oncology Authors: Yaping Yang Liang Jin Yudong Li Nanyan Rao Chang Gong Shunrong Li Jiannan Wu Jinghua Zhao Linxiaoxiao Ding Fengxia Gan Jun Zhang Ruifa Feng Zhenzhen Liu Qiang Liu Source Type: research

Characteristics of Patients Treated for Breast Cancer Associated Breast Oedema at a UK Tertiary Hospital
Purpose: Breast oedema can occur following breast conserving treatment and is associated with breast pain, reduced quality of life and poor body image [1]. The incidence and risk factors for breast oedema are much less well studied than arm lymphoedema, and it may go under-recognised by clinicians and under-reported by patients [1]. We aimed to describe the characteristics of patients treated by the breast oedema service, who had received radiotherapy for breast cancer at a tertiary centre. (Source: Clinical Oncology)
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: F. Wilson, K. Clark, C. Anandadas Source Type: research

Clinical characteristics and prognostic factors of male breast cancer in China
ConclusionIncreased age, bigger tumor size, higher TNM stage, and lower histological differentiation grade were associated with poor MBC prognosis, and LMR, PLR, and NLR might be potential predictors for MBC prognosis. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 8, 2024 Category: Cancer & Oncology Source Type: research

Mammographic surveillance after breast cancer
Br J Radiol. 2024 Mar 6:tqae043. doi: 10.1093/bjr/tqae043. Online ahead of print.ABSTRACTEarly detection of local recurrence has been shown to improve survival. What is unclear is how frequently mammography should be performed, how long surveillance should continue and how the answers to these questions vary with tumour pathology, patients age and surgery type. Many of these questions are not directly answerable from the current literature. While some of these questions will be answered by the Mammo50 study, evidence from local recurrence rates, tumour biology and the lead time of mammography can be used to guide policy. Y...
Source: The British Journal of Radiology - March 7, 2024 Category: Radiology Authors: Andy Evans Janet Dunn Peter Donnelly Source Type: research

This might surprise you
I was diagnosed with primary breast cancer in May 2022 at the age of 37. I underwent chemotherapy (8 cycles), breast-conserving surgery, and radiotherapy (15 doses over 3 weeks) as well as a host of other treatments. I am doing well now, but my life has been permanently altered. (Source: Journal of Medical Imaging and Radiation Sciences)
Source: Journal of Medical Imaging and Radiation Sciences - March 6, 2024 Category: Radiology Authors: Hayley Gullen Tags: Medical Radiation Sciences Narratives Source Type: research

Survival Outcomes Based on Axillary Surgery in Ductal Carcinoma < em > In Situ < /em > : A Nationwide Study From the Korean Breast Cancer Society
CONCLUSION: The decision to perform axillary surgery in patients with a final diagnosis of pure DCIS does not affect the prognosis, regardless of the breast surgical method. Furthermore, regardless of the breast surgical method, axillary surgery, including SLNB, should be considered for high-risk patients, such as those with large tumors. This may reduce unnecessary axillary surgery and enhance the patients' quality of life.PMID:38433090 | DOI:10.4048/jbc.2023.0221 (Source: Journal of Breast Cancer)
Source: Journal of Breast Cancer - March 3, 2024 Category: Cancer & Oncology Authors: Bong Kyun Kim Joohyun Woo Jeeyeon Lee Eunhye Kang Soo Yeon Baek Seokwon Lee Hyouk Jin Lee Jina Lee Woo Young Sun Korean Breast Cancer Society Source Type: research

Long-term results of intraoperative multicatheter breast implant (IOMBI) for accelerated partial breast irradiation (APBI) on early breast cancer patients
CONCLUSION: IOMBI&PHDRBT program reports excellent long-term oncological outcomes, with a reduction from unnecessary irradiation exposure which translates into low long-term toxicity and good cosmesis outcomes, especially on well-selected APBI patients.PMID:38432310 | DOI:10.1016/j.radonc.2024.110193 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - March 3, 2024 Category: Radiology Authors: Marta Gimeno-Morales Rafael Mart ínez-Monge Adriana Martinez-Lage Paola Anna Jablonska Javier Blanco Fernando Mart ínez-Regueira Natalia Rodriguez-Spiteri Bego ña Olartecoechea Luis Ramos Luis Pina Insausti Arlette Elizalde Marta Abengozar Mauricio Cam Source Type: research

Survival Outcomes Based on Axillary Surgery in Ductal Carcinoma < em > In Situ < /em > : A Nationwide Study From the Korean Breast Cancer Society
CONCLUSION: The decision to perform axillary surgery in patients with a final diagnosis of pure DCIS does not affect the prognosis, regardless of the breast surgical method. Furthermore, regardless of the breast surgical method, axillary surgery, including SLNB, should be considered for high-risk patients, such as those with large tumors. This may reduce unnecessary axillary surgery and enhance the patients' quality of life.PMID:38433090 | PMC:PMC10912575 | DOI:10.4048/jbc.2023.0221 (Source: Journal of Breast Cancer)
Source: Journal of Breast Cancer - March 3, 2024 Category: Cancer & Oncology Authors: Bong Kyun Kim Joohyun Woo Jeeyeon Lee Eunhye Kang Soo Yeon Baek Seokwon Lee Hyouk Jin Lee Jina Lee Woo Young Sun Korean Breast Cancer Society Source Type: research